M&A definitely a possibility for this little Aussie start up. US$1bn starting price would be nice.
Accelerate R&D. Pharma companies acquiring biotech assets can reduce the projected timeline for assets in the pipeline by at least 30 percent, on average. Success requires R&D integration that taps the power of the acquirer’s R&D system while preserving the target’s unique capabilities.
https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life#
Deloitte report;
With big pharma continuing to face loss of exclusivity events across various therapeutic areas, we believe 2024 will be another strong year for big pharma to plug portfolio gaps through M&A.
https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html
In search of growth: Pharma deals target precommercial biotech assets
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
0.005(0.83%) |
Mkt cap ! $67.73M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 61.0¢ | 61.0¢ | $1.684K | 2.761K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 26677 | 60.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.5¢ | 10266 | 1 |
View Market Depth
| Last trade - 09.59am 17/09/2025 (20 minute delay) ? |
| LTP (ASX) Chart |